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ever, early transplant-related mortality (TRM) was similar in both
groups. Besides both the frequency of acute and chronic GvHD
were not affected by the intensity of conditioning regimen. In
median 24.2 months (0.2-36 ms) of follow-up period, 3-year-
probability of DFS and OS in RIC compared to MA were 34.7 %
vs 46.9 % (log-analysis, p0.31) and 61.2 % vs 47.2 % (p0.37),
respectively. Conclusion: We observed less regimen related tox-
icity in RIC group as expected. Although the incidence of disease
relapse was more frequent in RIC group than MA group, both
DFS and OS were found in similar rates in both regimen. In CML
patients RIC regimen could be preferable instead of a MA regimen,
in high risk transplant candidates. We have still no evidence for
RIC about durable control of CML. After the completion of an
ongoing prospective and randomized phase III study in CML
comparing the RIC with MA in our center; we will extensively
evaluate the impact of RIC at allogeneic transplantation.
Transplantation data
Variables RIC group (n25) p MA group (n48)
Median CD34 (10e6/
BW kg) (range)
4.63 (2.49-13.16) 0.283 4.85 (0.36-18.90)
Median MNC (10e8/
BW kg) (range)
4.31 (0.98-19.15) 0.953 4.79 (0.55-19.15)
Median CD3 (10e8/
BW kg) (range)
21.70 (1.00-100.26) 0.071 25.10 (1.0-294.54)
Median Gratwohl
Score (range)
2 (1-4) 0.795 2 (1-4)
Engraftment
kinetics
Neutrophil>
0.5109/L,
median days
(range)
15 (0-20) 0.699 14 (10-32)
Platelet> 20109/L,
median days
(range)
10 (0-15) <0.0001* 13.5 (8-32)
Mucositis (Present/
Absent)
11/14 <0.0001* 45/3
Median grade of
mucositis (range)
0 (0-3) <0.0001 2 (0-4)
Median days of
mucositis (range)
0 (0-14) <0.0001* 7 (0-20)
Febrile episode
(Present/Absent)
11/14 <0.0001* 45/3
Median incidence of
febrile episode, n
0 (0-2) <0.0001* 1 (0-3)
Median days of
febrile episode
(range)
0 (0-8) 0.008* 2 (0-15)
TPN use 22% <0.0001* 77%
Acute GvHD 34.8% 0.785 29.8%
Chronic GvHD 76.2% 0.504 72.5%
Early transplant-
related mortality
12.0% 0.522 20.8%
Relapse 52% 0.001* 26%
3-year- probability
of DFS
34.67%  10.62% 0.314 46.85%  7.89%
3-year- probability
of OS
61.24%  10.24% 0.367 47,19%  7.85%
*p0.05
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C-REACTIVE PROTEIN (CRP) MAY PREDICT TRANSPLANT-RELATED
MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
(HCT)
Artz, A.S.1, Wickrema, A.1, Stock, W.1, Daugherty, C.1, Godley, L.1,
Kocherginsky, M.1, Odenike, O.1, Pollyea, D.1, Rich, E.1, Ulsazek, J.1,
Larson, R.1, van Besien, K.1 1University of Chicago Pritzerk School of
Medicine, Chicago, IL.
Current prognostic factors for transplant related mortality
(TRM) are disease status, the presence of comorbid conditions, and
performance status. Each of these measures has problems of sen-
sitivity and discriminative capacity. CRP, a marker of systemic
inﬂammation, has shown considerable value in non-HCT setting
to predict vascular events and overall survival(OS). We hypothe-
sized that elevated CRP would predict for worse HCT outcome.
Using a highly sensitive CRP assay, pre-HCT CRP levels were
analyzed in 41 consecutive patients with MDS or AML who un-
derwent HCT after a preparative regimen of ﬂudarabine (125
mg/m2 IV total), melphalan (140 mg/m2 IV total) and alemtu-
zumab (100 mg IV total). The median age was 52 years and 11/41
had active had active disease at HCT. The median CRP level was
20.6 mg/L and the mean was 38.5 mg/L (range 0.3 to 180). Six
month TRM was 23% with a median follow-up for survivors of 15
months. There was a signiﬁcant association between higher pre-
HCT CRP levels and TRM (P 0.03). CRP levels above the
median had a hazard ratio of 3.2 (P  0.07). CRP also showed an
association with overall survival (OS) (P 0.07) of borderline
statistical signiﬁcance. CRP remained predictive of TRM after
adjusting for disease status (P  0.06), charlson comorbidity index
(P  0.03), kaplan-feinstein comorbidity index (P  0.01), ECOG
performance status (P0.07) and age over 50 (P0.04). We con-
clude that in HCT recipients, the independent prognostic value of
CRP for TRM suggests the potential to enhance estimates of HCT
outcome in addition to standard prognostic factors. Prospective
studies in larger patient cohorts should be pursued to conﬁrm the
independent value of CRP and other pro-inﬂammatory cytokines
on HCT outcome.
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THIOTEPA BASED CONDITIONING REGIMEN IN 374 PATIENTS UNDER-
GOING ALLOGENEIC STEM CELL TRANSPLANTS FROM RELATED OR
UNRELATED DONORS
Bacigalupo, A.1, Gualandi, F.1, Occhini, D.1, Bregante, S.1,
Lamparelli, T.1, Raiola, A.M.1, Ibatici, A.1, Di Grazia, C.1,
Dominietto, A.1, Bruno, B.1, van Lint, M.T.1, Frassoni, F.1 1Hematol-
ogy Division, S.Martino’s Hospital, Genova, Italy.
Background:The Perugia group introduced thiotepa (THIO) in
allogeneic stem cell transplants (HSCT): we have developed
THIO based conditioning regimens in combination with cyclo-
phopshamide (CY), Fludarabine (FLU), melphalan (MEL) or TBI
200 mainly for patients above the age 45.
Aim of the study: assess the outcome of patients undergoing an
allogeneic HSCT with a THIO based conditioning regimen.
Patients. 374 patients were allografted with a THIO based
regimen, between 1994 and 2005, from HLA identical siblings
(SIB) (n221) or family partially mismatched (n67) or unrelated
(n86) donors. Median patient age was 48 years (range16-.67).
The stem cell source was unmanipulated in all cases , either bone
marrow (n276) or peripheral blood (n98). The conditioniong
regimens were classiﬁed as reduced intensity (n177) (THIO-CY
or THIO-FLU) or intensiﬁed (n197) (THIOCY supple-
mented with MEL or TBI). The disease was in 1stCR (n221) or
more advanced phase (n153). Patients had chronic myeloprolif-
erative disorders (n123), acute leukemia (n120), myelodisplasia
(n46), other (n85, including lymphoma and myeloma). All,
patients received cyclosporin methotrexate GvHD prophylaxis;
anti-thymocyte globulin was added for alternative donor trans-
plants. The median follow up for surviving patients is 5 years
(range 1-12 years)
Results: The overall actuarial 10 year survival is 40%, (60% vs
30% in CR1 or CR1 disease). The cumulative incidence (CI) of
transplant related mortality (TRM) at 10 years is 29% (18% vs 36%
for CR1 or CR1 disease); TRM for CR1 patients grafted from
identical siblings (n94) is 12%. Acute GvHD grade III-IV was
seen in 6% of sibling HSCT and 12% of alternative donor grafts.
The CI of relapse related death (RRD) at 10 years was 27% (18% vs
32% in CR1 or CR1). There was no effect of patient age, nor of
stem cell source on survival. In multivariate analysis on survival,
signiﬁcant predictors were disease phase (RR 2.4 of death for
patients beyond CR1) and intensity of the conditioning (RR 1.66
for intensiﬁed regimens); these two variables also predicted TRM;
disease phase predicted RRD.
Conclusions: This study shows that THIO based conditioning
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regimens produce encouraging long term survival, with a low
incidence of GvHD and low toxicity, especially in patients with
early disease. The addition of MEL or TBI reduces RRD, but
increases signiﬁcantly TRM and does not improve survival . Dis-
ease phase remains a major predictor of outcome.
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KEPIVANCE USE IN ALLOGENEIC STEM CELL TRANSPLANTATION
Bayer, R.-L.1, Kim, B.1, John, V.1, Devoe, C.1, Cannon, M.1,
Klocke, J.1, Gissinger, D.1 1North Shore University Hospital, Manhas-
set, NY.
Kepivance (palifermin) is a human keratinocyte growth factor
produced by recombinant DNA technology. Kepivance is indi-
cated to decrease the incidence and duration of severe oral mu-
cositis in patients with hematologic malignancies receiving myelo-
toxic therapy requiring hematopoiectic stem cell support. Graft vs.
host disease remains as one of the major obstacles in allogeneic
stem cell transplantation. The role inﬂammatory cytokines play in
GVHD is well known. It has been postulated that if mucositis can
be lessened , cytokine storm will be less and hopefully GVHD.
When looking at the allogeneic stem cell transplant patients during
2005 and 2006 at our institution a trend for a decrease in severity
of acute GVHD was noted in patients treated with Kepivance (60
mcg / kg). We reviewed 10 patients prior to the institution of
Kepivance and 10 after. Only 6 of 10 patients received all six doses
of the drug. 4 out of 10 received only 5 doses. In both groups 8/10
patients had reduced intensity transplants and 2/10 had fully abla-
tive transplants. Average length of stay was 40 days for those
patients who received the drug and 43 for those who did not.
There did not seem to be any major differances between the
incidence of oral and GI mucositis or in the use of narcotics and IV
antibiotics. 9 out of 10 patients who did not get Kepivance had
neutropenic fever and all 10 with Kepivance did. With respect to
GVHD 3/10 who did not get Kepivance developed acute GVHD
and 2/10 patients who received the drug develped acute GVHD. In
the non Kepivance group 2 patients had grade 3/4 GVHD, and one
had grade 2. In the Kepivance group 2 patients had grade 2
GVHD. In the kepivance group 5 patients completed all planned
methotrexate doses for GVHD prophylaxis, and 8 patients in the
non-kepivance group. This review suggests that Kepivance may
lessen the severity of acute GVHD, but not via the mechanism
described above.
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DIFFERENTIAL REQUIREMENT FOR NKG2D IN THE REJECTION OF
HAPLOMISMATCHED AND MHC-I DEFICIENT BONE MARROW
Benjamin, J.E.1, Lanier, L.L.1 1University of Californa, San Francisco,
San Francisco, CA.
Mouse Natural Killer (NK) cells mediate rejection of MHC-
mismatched or MHC-deﬁcient bone marrow allografts. Coun-
teracting activating and inhibitory signals regulate NK cell
activity. The ability of F1 mice to reject parental bone marrow
(BM) cells (hybrid resistance) has been attributed to the pres-
ence in the recipient of a subset of NK cells that lack inhibitory
receptors for the MHC class I antigens expressed by the donor
cells. Evidence supporting the “missing self” hypothesis of hy-
brid resistance was provided by demonstration that MHC
class-I deﬁcient donor BM is rejected by otherwise syngeneic
recipients. We have previously demonstrated a role for
NKG2D, an activating NK cell receptor, in rejection of Balb/c
(H-2d) parental BM by (Balb/c x C57Bl/6; H-2b/d) F1 (CB6F1)
recipient mice. NKG2D ligands are expressed on the regener-
ating myeloid BM cells in Balb/c and NOD mice but not
substantially on the regenerating C57Bl/6 BM cells. Moreover,
the rejection of Balb/c BM by CB6F1 recipients was blocked by
a neutralizing anti-NKG2D monoclonal antibody. The purpose
of this study was to determine whether NKG2D blockade was
sufﬁcient to prevent rejection of MHC-I deﬁcient BM. Beta-2
microglobulin deﬁcient (B2M-/-) Balb/c or NOD bone marrow
was transplanted into irradiated CB6F1 mice that had been
pretreated with neutralizing antibodies to NKG2D. In contrast
to results with wild-type Balb/c or NOD BM whose rejection
was prevented by anti-NKG2D, B2M-/- donor cells were re-
jected despite NKG2D blockade. Furthermore, syngeneic
MHC class I Balb/c recipients were able to reject B2M-/-
Balb/c donors despite NKG2D blockade. These results suggest
that rejection of MHC class I-bearing BM requires activation
via NKG2D, whereas MHC class I-deﬁcient BM elicit a sufﬁ-
ciently strong NK response that augmentation by NKG2D
signaling is not essential for the rejection. Therefore, the hybrid
resistance model in which MHC class I-bearing BM are used for
transplantation may better reﬂect the situation in human hema-
topoietic stem cell transplantation.
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DETERMINATION OF ALEMTUZUMAB DOSE FOR REDUCED INTENSITY
CONDITIONING IN ALLOGENEIC TRANSPLANTATION
Bigelow, C.L.1, Elkins, S.L.1, Herrin, V.E.1, Hardy, C.L.1, Files, J.C.1
1University of Mississippi Medical Center, Jackson, MS.
From June, 2002, to August, 2006, our institution utilized
reduced intensity conditioning (RIC) regimens for 40 adult
at-risk older patients or those with comorbid conditions. Ma-
lignancies included multiple myeloma, AML, CML, NHL,
MDS, CLL and one renal cell carcinoma. Thirteen (32%) were
in CR at time of transplant while 27 (68%) had relapsed or
refractory disease. Median age was 50 years (range 24-66) and
median follow-up was eight months (1-36 months). Nine pa-
tients were single antigen or allele mismatches at either A, B or
DR. The other 31 patients were 6/6 or better antigen matches
at A, B and DR. Three RIC regimens were used: ﬂudarabine 30
mg/m2 x 5 days and melphalan 140 mg/m2 x 1 day in all groups,
and Alemtuzumab 20 mg/d x 5 days (protocol 1), x 3 days
(protocol 2), and x 2 days (protocol 3). Twenty-three patients
received MUD products and 17 received MRD products; cell
source was bone marrow (17), PBSC (19), cord blood (one) and
combination products (3). All patients received an adequate
CD34 cell dose or TNC dose (cord blood transplant). GVHD
prophylaxis was tacrolimus tapering after day 100 and myco-
phenolate mofetil tapering after day 30. Determination of the
optimal dose of Alemtuzumab was a goal of this study. All
patients except one achieved a WBC graft. Relapse or disease
progression occurred in only 37% of protocol 3, 40% of pro-
tocol 2 and 67% of protocol 1. Although Alemtuzumab dose was
given in a standard fashion not adjusted for body weight or
surface area it was found that lack of consideration of patient
size did not represent the intent of the given protocols. Weight-
based Alemtuzumab dose adjustment showed that a much
broader dose range than expected had occurred. Those receiv-
ing protocol 1 were in a dose range of 1.01-1.90 mg/kg; for
protocol 2 the range was 0.36-1.08 mg/kg; for protocol 3 the
range was 0.36-0.70, overlapping the previous group. The me-
dian dose of Alemtuzumab for the cohort was 0.68 mg/kg. A
clustering of acute GVHD grades I-II appeared below the
median dose at approximately 0.55 mg/kg; only one patient had
grade IV acute GVHD. In summary, formulation of a condi-
tioning protocol that balances engraftment and recurrence of
primary disease on the backdrop of a newly reconstituted im-
mune system is problematic. These data indicate that using the
patient’s body weight in the determination of an optimal Ale-
mtuzumab dose is a more reasonable approach to developing
and standardizing RIC protocols with this drug.
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NONMYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
(NST) FOR HEMATOLOGIC MALIGNANCIES (HM) USING PENTOSTATIN/
LOW-DOSE TOTAL BODY IRRADIATION (PT-TBI)
Bociek, R.G.1, Talmadge, J.E.1, Loberiza, F.1, Kuszynski, C.A.1,
Bierman, P.J.1, Vose, J.M.1, Devetten, M.P.1, Maness, L.J.1,
Armitage, J.O.1, Joshi, S.1, Wisecarver, J.L.1, Enke, C.A.1,
McGuire, T.1, Bernal, K.1, Pavletic, S.Z.2 1University of Nebraska
Medical Center, Omaha, NE; 2National Institutes of Health, Washing-
ton, DC.
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